Skip to main content
Premium Trial:

Request an Annual Quote

GenOway Raises $37.4M in Alternext IPO

NEW YORK (GenomeWeb News) – GenOway, a French firm that develops transgenic mice and rats, began trading on Euronext’s Alternext exchange on April 5, the company said this week.
 
The company raised €27.7 million ($37.4 million) in its initial public offering, trading 5.6 million shares at €4.96 per share.
 
The company’s shares are trading at €6 today.
 
The Alternext, which opened two years ago, is a Euronext market designed for small and mid-cap companies.
 
GenOway develops genetically modified rat and mouse models for use in in vivo target validation and drug development.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.